References
- Kumari A, Brendel C, Hochhaus A, et al. Low BCR-ABL expression levels in hematopoietic precursor cells enable persistence of chronic myeloid leukemia under imatinib. Blood 2012;119:530–539.
- Bonifazi F, De Vivo A, Rosti G, et al. Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. Blood 2001;98:3074–3081.
- Carter BZ, Mak DH, Cortes J, et al. The elusive chronic myeloid leukemia stem cell: does it matter and how do we eliminate it?Semin Hematol 2010;47:362–370.
- Kantarjian H, O’Brien S, Jabbour E, et al. Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. Blood 2012;119:1981–1987.
- Simonsson B, Hjorth-Hansen H, Bjerrum OW, et al. Interferon alpha for treatment of chronic myeloid leukemia. Curr Drug Targets 2011;12:420–428.
- Lipton JH, Khoroshko N, Golenkov A, et al. Phase II, randomized, multicenter, comparative study of peginterferon-alpha-2a (40 kD) (Pegasys) versus interferon alpha-2a (Roferon-A) in patients with treatment-naïve, chronic-phase chronic myelogenous leukemia. Leuk Lymphoma 2007;48:497–505.
- Li YF, Deng ZK, Xuan HB, et al. Prolonged chronic phase in chronic myelogenous leukemia after homoharringtonine therapy. Chin Med J (Engl) 2009;122:1413–1417.
- Quintas-Cardama A, Kantarjian H, Garcia-Manero G, et al. Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy. Cancer 2007;109: 248–255.
- Li YF, Liu X, Liu DS, et al. The effect of homoharringtonine in patients with chronic myeloid leukemia who have failed or responded suboptimally to imatinib therapy. Leuk Lymphoma 2009;50: 1889–1891.
- O’Brien S, Talpaz M, Cortes J, et al. Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia. Cancer 2002;94:2024–2032.
- Shi YY, Cao WK, Liu XN, et al. Effects of interferon-α combined with homoharringtonine on K562 cell proliferation and β-catenin expression. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2012;20: 43–47.
- Quintas-Cardama A, Cortes J. Omacetaxine mepesuccinate-a semisynthetic formulation of the natural antitumoral alkaloid homoharringtonine, for chronic myelocytic leukemia and other myeloid malignancies. Idrugs 2008;11:356–372.
- Stone RM, Donohue KA, Stock W, et al. A phase II study of continuous infusion homoharringtonine and cytarabine in newly diagnosed patients with chronic myeloid leukemia: CALGB study 19804. Cancer Chemother Pharmacol 2009;63:859–864.
- Noda T, Nagano H, Takemasa I, et al. Activation of Wnt/ beta-catenin signalling pathway induces chemoresistance to interferon-alpha/5-fluorouracil combination therapy for hepatocellular carcinoma. Br J Cancer 2009;100:1647–1658.
- Minami Y, Stuart SA, Ikawa T, et al. BCR-ABL-transformed GMP as myeloid leukemic stem cells. Proc Natl Acad Sci USA 2008;105: 17967–17972.
- Hu Y, Chen Y, Douglas L, et al. Beta-catenin is essential for survival of leukemic stem cells insensitive to kinase inhibition in mice with BCR-ABL-induced chronic myeloid leukemia. Leukemia 2009;23:109–116.
- McWeeney SK, Pemberton LC, Loriaux MM, et al. A gene expression signature of CD34 + cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib. Blood 2010;5:315–325.
- Nagao R, Ashihara E, Kimura S, et al. Growth inhibition of imatinib-resistant CML cells with the T315I mutation and hypoxia-adaptation by AV65--a novel Wnt/β-catenin signaling inhibitor. Cancer Lett 2011;312:91–100.
- Li YF, Deng Z, Din BH, et al. Effect of homoharringtonine on bone marrow CD34 + CD11 + cells in patients with chronic myelogenous leukemia. Leuk Lymphoma 2012;53:934–939.